[Use of Highly Concentrated Polyunsaturated Fatty Acids for Prevention of Complications After Myocardial Infarction. Cost-Utility Analysis].

Use of highly concentrated ethyl esters of polyunsaturated fatty acids after myocardial infarction (MI) and in patients with heart failure was associated with lower mortality. The goal of this analysis was to perform cost-utility analysis of the use of highly concentrated ethyl esters of polyunsaturated fatty acids after MI (with help of a Markov model) and to find whether its use in some group of patients led to decrease in budget costs. As a result, we have shown that use of highly concentrated ethyl esters of polyunsaturated fatty acids after MI leads to increase in quality-adjusted life expectancy on 0.5 QALY, with incremental cost-effectiveness ratio of 105 thousand rubles per QALY, and net monetary benefit of 780.5 thousand rubles. In the patient subpopulation that receives highly concentrated ethyl esters of polyunsaturated fatty acids for arrhythmia prevention after coronary artery bypass the estimated decrease of budget cost varies between 6 and 50% depending on denominator used.